Inhibition of SARS-CoV-2 Infection by the Cyclophilin Inhibitor Alisporivir (Debio 025).
Antimicrob Agents Chemother
; 64(7)2020 06 23.
Article
de En
| MEDLINE
| ID: mdl-32376613
ABSTRACT
Cyclophilins play a key role in the life cycle of coronaviruses. Alisporivir (Debio 025) is a nonimmunosuppressive analogue of cyclosporine with potent cyclophilin inhibition properties. Alisporivir reduced SARS-CoV-2 RNA production in a dose-dependent manner in Vero E6 cells, with a 50% effective concentration (EC50) of 0.46 ± 0.04 µM. Alisporivir inhibited a postentry step of the SARS-CoV-2 life cycle. These results justify rapidly conducting a proof-of-concept phase 2 trial with alisporivir in patients with SARS-CoV-2 infection.
Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Pneumopathie virale
/
Ciclosporine
/
Infections à coronavirus
/
Cyclophilines
/
Betacoronavirus
Limites:
Animals
/
Humans
Langue:
En
Journal:
Antimicrob Agents Chemother
Année:
2020
Type de document:
Article
Pays d'affiliation:
France